CDKN2A and osteosarcoma: Taken together, our results illustrate that there is a clear subset of osteosarcoma patients (20–23%) for which CDK4/CDK6 inhibition might be promising and that loss of p16 protein expression or overexpression of CDK6, combined with intact Rb, may serve as a biomarker to select eligible patients.